Table 5.

Treatment of Patients with Osteoporosis or Low Bone Mass

	Stage A n=1875	Stage C n=1875	p
Patient prescribed antiresorptive therapy and/or anabolic therapy	(n=1237)	(n=1188)
	79%	82%	0.038
Current therapies	(n=975)	(n=976)
Bisphosphonate	80%	77%	0.245
Calcitonin	3%	3%	>0.999
Estrogen	3%	1%	0.041
Parathyroid hormone	6%	4%	0.086
Estrogen agonist/antagonist	5%	7%	0.101
RANKL inhibitor	5%	8%	0.028
Other	5%	5%	0.921
For patients with history of hip or vertebral fracture, following actions occurred within 6 months of fracture (all that applied)	(n=1231)	(n=1301)
Central DXA measurement	20%	20%	0.632
Pharmacologic treatment prescribed	11%	14%	0.026
None of the above	69%	67%	<0.001
Adherence to osteoporosis-related medications assessed within the last 12 months	(n=1136)	(n=1106)
	88%	96%	<0.001